Efficacy of omalizumab in chronic spontaneous urticaria refractory to conventional therapy: Analysis of 110 patients in real-life practice

Expert Opinion on Biological Therapy

Volumn 13, Issue 9, 2013, Pages 1225-1228

  Labrador Horrillo, Moises ^a   Valero, Antonio ^b   Velasco, Manuel ^c   Jáuregui, Ignacio ^d   Sastre, Joaquin ^e   Bartra, Joan ^b   Silvestre, Juan Francisco ^f   Ortiz De Frutos, Javier ^g   Gimenez Arnau, Ana ^a   Ferrer, Marta ^h  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c HOSPITAL ARNAU DE VILANOVA   (Spain)

^d HOSPITAL DE BASURTO   (Spain)

^e Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^f UNIVERSITY OF ALICANTE   (Spain)

^g HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^h UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Chronic spontaneous urticaria; Chronic urticaria; CSU; Omalizumab

Indexed keywords

OMALIZUMAB;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADULT; AGED; ARTICLE; ASYMPTOMATIC DISEASE; CHRONIC SPONTANEOUS URTICARIA; CHRONIC URTICARIA; DESCRIPTIVE RESEARCH; DRUG EFFICACY; DRUG SAFETY; FEMALE; HOSPITAL; HUMAN; MAJOR CLINICAL STUDY; MALE; OFF LABEL DRUG USE; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

EID: 84881503899     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2013.822484     Document Type: Article

References (13)

1. Zuberbier T, Asero R, Bindslev-Jensen C, et al. EAACI/GA2LEN(/EDF/WAO guideline: management of urticaria. Allergy 2009; 64: 1427-43
2. Sanchez-Borges M, Asero R, Ansotegui IJ, et al. Diagnosis and Treatment of Urticaria and Angioedema: a Worldwide Perspective. World Allergy Organ J 2012; 5(11): 125-47
3. Spector SL, Tan RA. Effect of omalizumab on patients with chronic urticaria. Ann Allergy Asthma Immunol 2007; 99(2): 190-3 (Pubitemid 47264781)
4. Kaplan AP, Joseph K, Maykut RJ, et al. Treatment of chronic autoimmune urticaria with omalizumab. J Allergy Clin Immunol 2008; 122(3): 569-73
5. Romano C, Sellitto A, De Fanis U, et al. Maintenance of remission with low-dose omalizumab in long-lasting, refractory chronic urticaria. Ann Allergy Asthma Immunol 2010; 104: 95-7
6. Maurer M, Altrichter S, Bieber T, et al. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J Allergy Clin Immunol 2011; 128(1): 202-9
7. Saini S, Rosen KE, Hsieh H-J, et al. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol 2011; 128(3): 567-73
8. Ferrer M, Gamboa P, Sanz ML, et al. Omalizumab is effective in nonautoimmune urticaria. J Allergy Clin Immunol 2011; 127(5): 1300-2
9. Buyukozturk S, Gelincik A, Demirturk M, et al. Omalizumab markedly improves urticaria activity scores and quality of life scores in chronic spontaneous urticaria patients: a real life survey. J Dermatol 2012
10. Nam YH, Kim JH, Jin HJ, et al. Effects of omalizumab treatment in patients with refractory chronic urticaria. Allergy Asthma Immunol Res 2012; 4(6): 357-61
11. Song CH, Stern S, Giruparajah M, et al. Long-term efficacy of fixed-dose omalizumab for patients with severe chronic spontaneous urticaria. Ann Allergy Asthma Immunol 2013; 110(2): 113-17
12. Maurer M, Rosén K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med 2013; 368(10): 924-35
13. Mlynek A, Zalewska-Janowska A, Martus P, et al. How to assess disease activity in patients with chronic urticaria? Allergy 2008; 63(6): 777-80 (Pubitemid 351591864)